靶向放射性药物高峰论坛

Past Event
We are excited to be presenting at this conference!
靶向放射治疗的临床药理学和模型引导的药物开发启示
Joshua Apgar, PhD
|Applied BioMath 副总裁兼科学事务全球负责人,Certara
- Learn how clinical pharmacology considerations and model-informed drug development (MIDD) concepts help streamline therapeutic index-focused discovery and drug development for TRTs.
- Learn how to craft strategies that comply with the FDA’s Project Optimus initiative to optimize oncology drug dosage.
- Understand dose optimization requirements for TRT in the clinical pharmacology regulatory landscape.
- Discover how MIDD, including quantitative systems pharmacology (QSP) and pharmacometrics, help drive rational drug design, patient selection, and inform dosage optimization.